Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clavic-Q-RE
- Development stage
- Preclinical
- Lead developer
- RGCC Group
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Clavic-Q-RE is an autologous, non-manipulated adoptive cell therapy developed by the Research Genetic Cancer Centre Group (RGCC) for the treatment of various cancers. Classified as a Cell Therapy Medicinal Product (CTMP) by the European Medicines Agency, it consists of a diverse population of immune cells—including monocytes, natural killer (NK) cells, dendritic cells, cytotoxic T lymphocytes, and plasma cells—isolated from the patient's own blood. These cells are already activated or differentiated *in vivo* against specific tumor antigens. The therapy is designed to bolster the patient's immune system by delivering these pre-activated effector cells back into the body to elicit a comprehensive anti-tumor response. It is indicated for both solid tumors and hematological malignancies, though it is excluded for use in central nervous system cancers due to the blood-brain barrier.
- Brand names
- Clavic-Q-RE
Beyond the preview
Go deeper on Clavic-Q-RE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clavic-Q-RE.